Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744834 | 0.78 | PSMB5 (0.40) | ACMSDPTGS2PSMB5PSMB1CCNE1 | |
| SCHEMBL30657553 | 0.75 | PTGS2 (0.49) | ACMSDPTGS2PSMB5CLCN2GRM2 | |
| SCHEMBL27173426 | 0.74 | PSMB5 (0.45) | PTGS2PSMB5PSMB1CCNE1CDK2 | |
| SCHEMBL2744786 | 0.72 | PSMB5 (0.34) | ACMSDPTGS2PSMB5PSMB1GRM2 | |
| SCHEMBL7209639 | 0.70 | PSMB5 (0.38) | PTGS2PSMB5PSMB1CCNE1CDK2 | |
| SCHEMBL15287144 | 0.67 | F2RL1 (0.44) | ACMSDCLCN2HDAC2GRM2 | |
| SCHEMBL3092798 | 0.66 | CSF1R (0.41) | ACMSDPTGS2PSMB5HDAC2GRM2 | |
| SCHEMBL11816684 | 0.66 | ACMSD (0.51) | ACMSDPTGS2HDAC2KMT2A | |
| SCHEMBL3092807 | 0.65 | HDAC1 (0.43) | ACMSDHDAC2CSF1R | |
| SCHEMBL11673820 | 0.65 | ACMSD (0.50) | ACMSDPTGS2HDAC2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274706-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6462069-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | AGOURON PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2001079198-A9 | PYRAZOLES FOR INHIBITING PROTEIN KINASE | AGOURON PHARMA (US) | 2002-05-16 | — | — | WO | disclosed |
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | LIGHPOINTE COMMUNICATION, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001079198-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | CDK3, CCNK, CDK1 | ACMSD 4464/4885PTGS2 397/4885PSMB5 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.